<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39081166</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Enterovirus A71 2A-S125A acts as an attenuated vaccine candidate, indicating a universal approach in developing enterovirus vaccines.</ArticleTitle><Pagination><StartPage>e29838</StartPage><MedlinePgn>e29838</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29838</ELocationID><Abstract><AbstractText>Enteroviruses are important human pathogens with diverse serotypes, posing a major challenge to develop vaccines for individual serotypes, the success of polio vaccines in controlling and eradicating polio, along with the recent emergence and high prevalence of enterovirus-caused infectious diseases, highlights the importance of enterovirus vaccine development. Given our previous report on enteroviruses weakened by the 2 A S/T125A mutation, we assessed the potential of the EV-A71 2A-125A mutant as a vaccine candidate to address this challenge. We found that the 2A-125A mutant caused transient mild symptoms, low viral loads, and no significant pathological changes mild pathological changes in hSCARB2-KI mice, producing long-lasting cross-neutralizing antibodies against two EV-A71 wild strains. Pre-exposure to the 2A-125A mutant substantially protected against the EV-A71 Isehara wild-type strain, causing minor pathologies, significantly reducing muscle and lung inflammation, and preventing neurological damage, with reduced viral loads in vivo. Pre-exposure also distinctly suppressed the expression of pro-inflammatory cytokines, correlating to the severity of clinical symptoms. Collectively, the EV-A71 2A-125A mutant was attenuated and could generate a robust and protective immune response, suggesting its potential as a vaccine candidate and global solution for specific enterovirus vaccine development.</AbstractText><CopyrightInformation>© 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Wenjia</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Changfa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yihong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>National Key R&amp;D Program of China under Grant number 2021YFC230170104</Agency><Country /></Grant><Grant><Agency>National Natural Science Foundation of China under Grant number 81974310</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="Y">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="Y">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087506" MajorTopicYN="N">Vaccine Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV‐A71 mutant</Keyword><Keyword MajorTopicYN="N">enteroviruses</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">serotype‐specific vaccines</Keyword><Keyword MajorTopicYN="N">viral pathogenesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>3</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39081166</ArticleId><ArticleId IdType="doi">10.1002/jmv.29838</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Zell R, Delwart E, Gorbalenya AE, et al. ICTV virus taxonomy profile: picornaviridae. J Gen Virol. 2017;98(10):2421‐2422. doi:10.1099/jgv.0.000911</Citation></Reference><Reference><Citation>Andino R, Kirkegaard K, Macadam A, Racaniello VR, Rosenfeld AB. The picornaviridae family: knowledge gaps, animal models, countermeasures, and prototype pathogens. J Infect Dis. 2023;228(6):427. doi:10.1093/infdis/jiac426</Citation></Reference><Reference><Citation>Lyu K, Wang GC, He YL, et al. Crystal structures of enterovirus 71 (EV71) recombinant virus particles provide insights into vaccine design. J Biol Chem. 2015;290(6):3198‐3208. doi:10.1074/jbc.M114.624536</Citation></Reference><Reference><Citation>Fischer TK, Simmonds P, Harvala H. The importance of enterovirus surveillance in a post‐polio world. Lancet Infect Dis. 2022;22(1):e35‐e40. doi:10.1016/S1473-3099(20)30852-5</Citation></Reference><Reference><Citation>Xia H, Wang P, Wang GC, et al. Human enterovirus nonstructural protein 2CATPase functions as both an RNA helicase and ATP‐independent RNA chaperone. PLoS Pathog. 2015;11(7):e1005067. doi:10.1371/journal.ppat.1005067</Citation></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008‐12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308‐318. doi:10.1016/S1473-3099(13)70342-6</Citation></Reference><Reference><Citation>Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol: Mech Dis. 2008;3:127‐155. doi:10.1146/annurev.pathmechdis.3.121806.151534</Citation></Reference><Reference><Citation>Hu Y, Musharrafieh R, Zheng M, Wang J. Enterovirus D68 antivirals: past, present, and future. ACS Infect Dis. 2020;6(7):1572‐1586. doi:10.1021/acsinfecdis.0c00120</Citation></Reference><Reference><Citation>Vogt MR, Wright PF, Hickey WF, De Buysscher T, Boyd KL, Crowe JE. Enterovirus D68 in the anterior horn cells of a child with acute flaccid myelitis. N Engl J Med. 2022;386(21):2059‐2060. doi:10.1056/NEJMc2118155</Citation></Reference><Reference><Citation>Zhu P, Ji W, Li D, et al. Current status of hand‐foot‐and‐mouth disease. J Biomed Sci. 2023;30(1):15. doi:10.1186/s12929-023-00908-4</Citation></Reference><Reference><Citation>Baggen J, Thibaut HJ, Strating JRPM, van Kuppeveld FJM. The life cycle of non‐polio enteroviruses and how to target it. Nat Rev Microbiol. 2018;16(6):368‐381. doi:10.1038/s41579-018-0005-4</Citation></Reference><Reference><Citation>Guo H, Li Y, Liu G, et al. A second open reading frame in human enterovirus determines viral replication in intestinal epithelial cells. Nat Commun. 2019;10(1):4066. doi:10.1038/s41467-019-12040-9</Citation></Reference><Reference><Citation>Abdullah SW, Wu J, Wang X, Guo H, Sun S. Advances and breakthroughs in IRES‐directed translation and replication of picornaviruses. mBio. 2023;14(2):e0035823. doi:10.1128/mbio.00358-23</Citation></Reference><Reference><Citation>Yu SF, Lloyd RE. Identification of essential amino acid residues in the functional activity of poliovirus 2A protease. Virology. 1991;182(2):615‐625. doi:10.1016/0042-6822(91)90602-8</Citation></Reference><Reference><Citation>Kräusslich HG, Nicklin MJ, Toyoda H, Etchison D, Wimmer E. Poliovirus proteinase 2A induces cleavage of eucaryotic initiation factor 4F polypeptide p220. J Virol. 1987;61(9):2711‐2718. doi:10.1128/JVI.61.9.2711-2718.1987</Citation></Reference><Reference><Citation>Lee KM, Chen CJ, Shih SR. Regulation mechanisms of viral IRES‐driven translation. TIM. 2017;25(7):546‐561. doi:10.1016/j.tim.2017.01.010</Citation></Reference><Reference><Citation>Borman AM, Le Mercier P, Girard M, Kean KM. Comparison of picornaviral IRES‐driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res. 1997;25(5):925‐932. doi:10.1093/nar/25.5.925</Citation></Reference><Reference><Citation>Feng Q, Langereis MA, Lork M, et al. Enterovirus 2Apro targets MDA5 and MAVS in infected cells. J Virol. 2014;88(6):3369‐3378. doi:10.1128/JVI.02712-13</Citation></Reference><Reference><Citation>Chen B, Wang Y, Pei X, Wang S, Zhang H, Peng Y. Cellular Caspase‐3 contributes to EV‐A71 2Apro‐mediated down‐regulation of IFNAR1 at the translation level. Virol Sin. 2020;35(1):64‐72. doi:10.1007/s12250-019-00151-y</Citation></Reference><Reference><Citation>Lu J, Yi L, Zhao J, et al. Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1. J Virol. 2012;86(7):3767‐3776. doi:10.1128/JVI.06687-11</Citation></Reference><Reference><Citation>Barral PM, Morrison JM, Drahos J, et al. MDA‐5 is cleaved in poliovirus‐infected cells. J Virol. 2007;81(8):3677‐3684. doi:10.1128/JVI.01360-06</Citation></Reference><Reference><Citation>Jensen KJ, Garmaroudi FS, Zhang J, et al. An ERK‐p38 subnetwork coordinates host cell apoptosis and necrosis during coxsackievirus B3 infection. Cell Host Microbe. 2013;13(1):67‐76. doi:10.1016/j.chom.2012.11.009</Citation></Reference><Reference><Citation>Wahid R, Mercer L, Gast C, et al. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. NPJ Vaccines. 2022;7(1):19. doi:10.1038/s41541-022-00437-5</Citation></Reference><Reference><Citation>Lambo TA. Eradication of smallpox. N Engl J Med. 1981;305(4):224. doi:10.1056/NEJM198107233050415</Citation></Reference><Reference><Citation>Barrett ADT. Polio endgame finish is in sight. Nature. 2023;619(7968):36‐38. doi:10.1038/d41586-023-01773-9</Citation></Reference><Reference><Citation>Mao Q, Wang Y, Bian L, Xu M, Liang Z. EV‐A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5(7):e75. doi:10.1038/emi.2016.73.</Citation></Reference><Reference><Citation>Duan H, Zhu M, Xiong Q, et al. Regulation of enterovirus 2A protease‐associated viral IRES activities by the cell's ERK signaling cascade: implicating ERK as an efficiently antiviral target. Antiviral Res. 2017;143:13‐21. doi:10.1016/j.antiviral.2017.03.018</Citation></Reference><Reference><Citation>Zhang H, Wang X, Wang Y, et al. Substituted 3‐benzylcoumarins 13 and 14 suppress enterovirus A71 replication by impairing viral 2Apro dependent IRES‐driven translation. Antiviral Res. 2018;160:10‐16. doi:10.1016/j.antiviral.2018.10.012</Citation></Reference><Reference><Citation>Wang Y, Zou W, Niu Y, et al. Phosphorylation of enteroviral 2Apro at Ser/Thr125 benefits its proteolytic activity and viral pathogenesis. J Med Virol. 2023;95(1):e28400. doi:10.1002/jmv.28400</Citation></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nature Med. 2009;15(7):798‐801. doi:10.1038/nm.1992</Citation></Reference><Reference><Citation>Fujii K, Nagata N, Sato Y, et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci U S A. 2013;110(36):14753‐14758. doi:10.1073/pnas.1217563110</Citation></Reference><Reference><Citation>Miwatashi W, Ishida M, Takashino A, et al. Mouse Scarb2 modulates EV‐A71 pathogenicity in neonatal mice. J Virol. 2022;96(15):e0056122. doi:10.1128/jvi.00561-22</Citation></Reference><Reference><Citation>Zhu J, Chen N, Zhou S, et al. Severity of enterovirus A71 infection in a human SCARB2 knock‐in mouse model is dependent on infectious strain and route. Emerg Microbes Infect. 2018;7(1):1‐13. doi:10.1038/s41426-018-0201-3</Citation></Reference><Reference><Citation>Wu Y, Qu Z, Xiong R, et al. A practical method for evaluating the in vivo efficacy of EVA‐71 vaccine using a hSCARB2 knock‐in mouse model. Emerg Microbes Infect. 2021;10(1):1180‐1190. doi:10.1080/22221751.2021.1934558</Citation></Reference><Reference><Citation>Sun C, Kang YF, Fang XY, et al. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV. Cell Host Microbe. 2023;31(11):1882‐1897.e10. doi:10.1016/j.chom.2023.09.011</Citation></Reference><Reference><Citation>Zhao GX, Bu GL, Liu GF, et al. mRNA‐based vaccines targeting the T‐cell epitope‐rich domain of Epstein Barr virus latent proteins elicit robust anti‐tumor immunity in mice. Adv Sci (Weinh). 2023;10(35):e2302116. doi:10.1002/advs.202302116</Citation></Reference><Reference><Citation>Skolnik JM, Morrow MP. Vaccines for HPV‐associated diseases. Mol Aspects Med. 2023;94:101224. doi:10.1016/j.mam.2023.101224</Citation></Reference><Reference><Citation>Moradpour J, Chit A, Besada‐Lombana S, Grootendorst P. Overview of the global vaccine ecosystem. Expert Rev Vaccines. 2023;22(1):749‐763. doi:10.1080/14760584.2023.2250433</Citation></Reference><Reference><Citation>Bessaud M, Delpeyroux F. Enteroviruses‐the famous unknowns. Lancet Infect Dis. 2020;20(3):268‐269. doi:10.1016/S1473-3099(19)30636-X</Citation></Reference><Reference><Citation>Kwong KWY, Xin Y, Lai NCY, et al. Oral vaccines: a better future of immunization. Vaccines. 2023;11(7):1232. doi:10.3390/vaccines11071232</Citation></Reference><Reference><Citation>Wahid R, Mercer LD, De Leon T, et al. Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials. Lancet Microbe. 2022;3(12):912. doi:10.1016/S2666-5247(22)00254-3</Citation></Reference><Reference><Citation>Fan X, Yue Y, Xiong S. Incorporation of a bi‐functional protein FimH enhances the immunoprotection of chitosan‐pVP1 vaccine against coxsackievirus B3‐induced myocarditis. Antiviral Res. 2017;140:121‐132. doi:10.1016/j.antiviral.2017.01.020</Citation></Reference><Reference><Citation>Henke A, Zell R, Stelzner A. DNA vaccine‐mediated immune responses in Coxsackie virus B3‐infected mice. Antiviral Res. 2001;49(1):49‐54. doi:10.1016/s0166-3542(00)00132-7</Citation></Reference><Reference><Citation>Lan J, Gao Z, Xiong H, et al. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime‐protein boost vaccination. Vaccine. 2011;29(40):6894‐6902. doi:10.1016/j.vaccine.2011.07.049</Citation></Reference><Reference><Citation>Zhang N, Zheng T, Chen Y, et al. Coxsackievirus B5 virus‐like particle vaccine exhibits greater immunogenicity and immunoprotection than its inactivated counterpart in mice. Vaccine. 2021;39(39):5699‐5705. doi:10.1016/j.vaccine.2021.07.095</Citation></Reference><Reference><Citation>Huang SW, Cheng D, Wang JR. Enterovirus A71: virulence, antigenicity, and genetic evolution over the years. J Biomed Sci. 2019;26(1):81. doi:10.1186/s12929-019-0574-1</Citation></Reference><Reference><Citation>Victorio CB, Xu Y, Ng Q, Meng T, Chow VT, Chua KB. Cooperative effect of the VP1 amino acids 98E, 145A and 169F in the productive infection of mouse cell lines by enterovirus 71 (BS strain). Emerg Microbes Infect. 2016;5(6):e60. doi:10.1038/emi.2016.56</Citation></Reference><Reference><Citation>Tee HK, Tan CW, Yogarajah T, et al. Electrostatic interactions at the five‐fold axis alter heparin‐binding phenotype and drive enterovirus A71 virulence in mice. PLoS Pathog. 2019;15(11):e1007863. doi:10.1371/journal.ppat.1007863</Citation></Reference><Reference><Citation>Zhou D, Zhao Y, Kotecha A, et al. Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2. Nat Microbiol. 2019;4(3):414‐419. doi:10.1038/s41564-018-0319-z</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>